FTSJ3

Across TCGA pan-cancer cohorts, FTSJ3 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated FTSJ3 data layer compared with 20 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher FTSJ3 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated FTSJ3 expression acts as an unfavorable survival marker, although some lineages such as LSCC and COAD show a favorable association.

PDAC, CCRCC, and LSCC are the cancer types where FTSJ3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	II,III,IV	0.321	0.707	<.001	37	view →
CCRCC	DFS	Median	III,IV	0.379	0.742	.001	21	view →
LSCC	DFS	Quartile	II,III,IV	0.949	0.569	.006	17	view →
LUAD	OS	Median	II,III,IV	0.337	0.908	.002	9	view →
COAD	DFS	Median	III,IV	1.000	0.846	.049	6	view →
HNSC	OS	Median	II,III,IV	0.932	0.993	.023	5	view →
GBM	OS	Median	All	0.644	0.387	.015	4	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

FTSJ3–PDAC (OS)

Open the PDAC breakdown →